QQQ   415.59 (-1.85%)
AAPL   164.79 (-1.35%)
MSFT   399.03 (-1.30%)
META   480.43 (-4.26%)
GOOGL   153.65 (-1.51%)
AMZN   174.04 (-2.89%)
TSLA   147.27 (-1.77%)
NVDA   778.40 (-8.07%)
AMD   146.30 (-5.66%)
NIO   3.80 (-5.00%)
BABA   68.93 (+0.07%)
T   16.48 (+0.92%)
F   12.07 (+0.08%)
MU   106.32 (-5.01%)
GE   148.44 (-2.94%)
CGC   8.03 (+2.55%)
DIS   112.25 (-0.16%)
AMC   3.17 (+8.56%)
PFE   25.89 (+1.97%)
PYPL   61.86 (-0.39%)
XOM   119.71 (+1.00%)
QQQ   415.59 (-1.85%)
AAPL   164.79 (-1.35%)
MSFT   399.03 (-1.30%)
META   480.43 (-4.26%)
GOOGL   153.65 (-1.51%)
AMZN   174.04 (-2.89%)
TSLA   147.27 (-1.77%)
NVDA   778.40 (-8.07%)
AMD   146.30 (-5.66%)
NIO   3.80 (-5.00%)
BABA   68.93 (+0.07%)
T   16.48 (+0.92%)
F   12.07 (+0.08%)
MU   106.32 (-5.01%)
GE   148.44 (-2.94%)
CGC   8.03 (+2.55%)
DIS   112.25 (-0.16%)
AMC   3.17 (+8.56%)
PFE   25.89 (+1.97%)
PYPL   61.86 (-0.39%)
XOM   119.71 (+1.00%)
QQQ   415.59 (-1.85%)
AAPL   164.79 (-1.35%)
MSFT   399.03 (-1.30%)
META   480.43 (-4.26%)
GOOGL   153.65 (-1.51%)
AMZN   174.04 (-2.89%)
TSLA   147.27 (-1.77%)
NVDA   778.40 (-8.07%)
AMD   146.30 (-5.66%)
NIO   3.80 (-5.00%)
BABA   68.93 (+0.07%)
T   16.48 (+0.92%)
F   12.07 (+0.08%)
MU   106.32 (-5.01%)
GE   148.44 (-2.94%)
CGC   8.03 (+2.55%)
DIS   112.25 (-0.16%)
AMC   3.17 (+8.56%)
PFE   25.89 (+1.97%)
PYPL   61.86 (-0.39%)
XOM   119.71 (+1.00%)
QQQ   415.59 (-1.85%)
AAPL   164.79 (-1.35%)
MSFT   399.03 (-1.30%)
META   480.43 (-4.26%)
GOOGL   153.65 (-1.51%)
AMZN   174.04 (-2.89%)
TSLA   147.27 (-1.77%)
NVDA   778.40 (-8.07%)
AMD   146.30 (-5.66%)
NIO   3.80 (-5.00%)
BABA   68.93 (+0.07%)
T   16.48 (+0.92%)
F   12.07 (+0.08%)
MU   106.32 (-5.01%)
GE   148.44 (-2.94%)
CGC   8.03 (+2.55%)
DIS   112.25 (-0.16%)
AMC   3.17 (+8.56%)
PFE   25.89 (+1.97%)
PYPL   61.86 (-0.39%)
XOM   119.71 (+1.00%)
Free Trial

Compare Stocks

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Compare

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
$1.39
+8.6%		$1.52
$1.15
▼
$2.98
$4.49M1.4516,089 shs5,343 shs
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-2.66%-18.94%-14.67%-10.49%-53.17%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
2.1632 of 5 stars		3.55.00.00.00.60.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
3.00
Buy$5.00259.71% Upside

Current Analyst Ratings

Latest LOK, FOXT, ARTL, and UAI Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/2/2024
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated RatingBuy ➝ Buy$5.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/A$4.12 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
-$9.29M-$3.14N/AN/AN/AN/A-61.68%-58.15%5/9/2024 (Estimated)

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
N/A
8.51
8.51

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
0.87%

Insider Ownership

CompanyInsider Ownership
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
6.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Artelo Biosciences, Inc. stock logo
ARTL
Artelo Biosciences
53.23 million3.01 millionNot Optionable

LOK, FOXT, ARTL, and UAI Headlines

SourceHeadline
Recap: Artelo Biosciences Q4 EarningsRecap: Artelo Biosciences Q4 Earnings
benzinga.com - March 25 at 1:13 PM
Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58Artelo Biosciences GAAP EPS of -$3.14 misses by $0.58
msn.com - March 25 at 1:13 PM
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business UpdateArtelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
globenewswire.com - March 25 at 8:00 AM
Artelo Biosciences Selected as a Finalist in Johnson & Johnsons Innovation ChallengeArtelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
globenewswire.com - March 12 at 9:15 AM
Artelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thArtelo Biosciences, Inc.: Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
finanznachrichten.de - February 15 at 10:34 AM
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20thArtelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
accesswire.com - February 15 at 9:00 AM
Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12
finance.yahoo.com - January 8 at 3:07 PM
Artelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in GermanyArtelo Biosciences Presents New Preclinical Data on ART12.11 at the 4th Annual Med-Cannabis 2023 Conference in Germany
finance.yahoo.com - December 5 at 9:22 AM
Promising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating RecommendationPromising Developments in Artelo Biosciences’ Cancer Therapies Drive Buy Rating Recommendation
markets.businessinsider.com - November 16 at 1:30 PM
Artelo Biosciences GAAP EPS of -$0.83 misses by $0.18Artelo Biosciences GAAP EPS of -$0.83 misses by $0.18
msn.com - November 13 at 3:50 PM
Artelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business UpdateArtelo Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - November 13 at 10:11 AM
Artelo Biosciences Inc ARTLArtelo Biosciences Inc ARTL
morningstar.com - November 7 at 11:39 PM
Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023Artelo Biosciences to Present Preclinical Data Showcasing Research on ART26.12 and ART12.11 in Anxiety and Depression at Neuroscience 2023
finance.yahoo.com - November 2 at 9:23 AM
Taking a look at what insiders are doing to gauge the Artelo Biosciences Inc. (ARTL)’s directionTaking a look at what insiders are doing to gauge the Artelo Biosciences Inc. (ARTL)’s direction
knoxdaily.com - September 7 at 7:19 PM
Artelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13thArtelo Biosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 13th
finance.yahoo.com - September 5 at 11:57 AM
Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)Analysts Offer Insights on Healthcare Companies: Larimar Therapeutics (LRMR), Artelo Biosciences (ARTL) and Unity Biotechnology (UBX)
markets.businessinsider.com - August 11 at 4:35 PM
Artelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.Artelo Biosciences (ARTL) Receives a Buy from Ladenburg Thalmann & Co.
markets.businessinsider.com - June 28 at 9:56 AM
Artelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic PainArtelo Unvails New Data On ART26.12 Demonstrating Positive Effects In Multiple Models Of Neuropathic Pain
msn.com - June 27 at 12:41 PM
Artelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society SymposiumArtelo Biosciences Announces Important New Data on ART26.12 Demonstrating Positive Effects in Multiple Models of Neuropathic Pain at the 33rd Annual International Cannabinoid Research Society Symposium
finance.yahoo.com - June 27 at 12:41 PM
Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)Analysts Offer Insights on Healthcare Companies: Artelo Biosciences (ARTL), Iterum Therapeutics (ITRM) and TScan Therapeutics (TCRX)
markets.businessinsider.com - May 18 at 8:34 AM
Artelo Biosciences: Q1 Earnings InsightsArtelo Biosciences: Q1 Earnings Insights
msn.com - May 11 at 7:26 PM
Artelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business UpdateArtelo Biosciences Reports First Quarter 2023 Financial Results and Provides Business Update
finance.yahoo.com - May 11 at 9:26 AM
Artelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight LossArtelo Biosciences Initiates the Phase 2a Portion of its CAReS Trial EvaluatingART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss
finance.yahoo.com - April 25 at 9:59 AM
Artelo Biosciences (ARTL) Gets a Buy from Maxim GroupArtelo Biosciences (ARTL) Gets a Buy from Maxim Group
markets.businessinsider.com - April 4 at 10:22 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Artelo Biosciences logo

Artelo Biosciences

NASDAQ:ARTL
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.